relapsing polychondritis
Jump to navigation
Jump to search
Introduction
Episodic & often progressive inflammatory disorder affecting the cartilage of the ear, nose & tracheobronchial tree.
Etiology
- idiopathic
- antibodies to type II collagen
- 30% have another connective tissue disease
Epidemiology
- most common between age 40-60, but may affect children or elderly
- relatively uncommon
- all races
Pathology
- inflammation & damage to cartilage
- depletion of proteoglycan from cartilage matrix
- inflammatory infiltrate of mononuclear cells & occasional plasma cells adjacent to involved cartilage
- neutrophils may be present in acute disease
- destruction of cartilage begins at outer edges & continues centrally
- lacunar breakdown & loss of chondrocytes
- degenerating cartilage is replaced by granulation tissue, & later by fibrosis & focal areas of calcification
- small focal areas of cartilage regeneration may be present
- immunoglobulin & complement detected by immunofluorescence at sites of involved cartilage
- loss of cartilage matrix hypothesized secondary to action of proteolytic enzymes released by chondrocytes & inflammatory cells activated by cytokines
Clinical manifestations
- involvement of ears, nose, larynx, trachea, & joints
- auricular chondritis (40%/85%)*
- both ears generally involved
- sudden onset of pain, tenderness & swelling of cartilagenous portion of ear
- earlobes are spared because they do not contain cartilage
- overlying skin is red or violaceous
- recurrent episodes result in droopy ears
- cochlear or vestibular dysfunction
- hearing loss (10%/30%)*
- tinnitus & or vertigo[3]
- nasal chondritis (25%/55%)*
- saddle nose deformity (20%/30%)*
- ocular deformity/disorder (20%/50%)*
- respiratory disease (25%/50%)*
- mucosal edema & strictures
- laryngeal chondritis or tracheal chondritis (50%)
- expiratory collapse of major airways
- collapse of laryngeal, tracheal or bronchial cartilage (late manifestation)
- airway obstruction requiring emergency tracheostomy
- hoarseness, non-productive cough
- pneumonia
- 50% of deaths due to respiratory complications
- arthritis (35%/50%)*
- aortic regurgitation ( /5%)*
- vasculitis (3%/10%)*
- other manifestations
- polyarthritis
- cardiac abnormalities
- aortic regurgitation (5%)
- pericarditis
- myocarditis
- conduction abnormalities
- skin lesions
- glomerulonephritis may occur in the absence of systemic vasculitis
- relapsing course with exacerbations & remissions
* (presenting/cumlative frequencies)
# images[9]
Diagnostic criteria
- 3 of the following 6
- recurrent bilateral auricular chondritis (90%)
- non-erosive inflammatory polyarthritis (65%)
- nasal chondritis (60%)
- ocular inflammation: conjuctivitis, keratitis, scleritis, episcleritis, uveitis (55%)
- laryngeal chondritis or tracheal chondritis (50%)
- cochlear &/or vestibular dysfunction: tinnitus &/or vertigo, neurosensory hearing loss (10%)[3]
Laboratory
- complete blood count (CBC)
- elevated erythrocyte sedimentation rate (ESR)
- serology
- rheumatoid factor (RF) & anti-nuclear antibody (ANA) are often positive in low titers
- antibodies to type II collagen are positive in most patients, but non-specific
- circulating immune complexes may be detected
- ANCA (cANCA or pANCA) are positive in some
- abnormal liver function tests (LFTs)
- polyclonal gammopathy may be present
- biopsy of cartilagenous portion of ear
Diagnostic procedures
- bronchoscopy if indicated
- pulmonary function testing with flow volume loops[3]
Radiology
- chest X-ray
- computed tomography (CT) of thorax
- tracheal thickening (spares posterior membrane)
- few tracheal calcifications[3] Differential diagnisis:
- granulomatosis with polyangiitis (Wegener's granulomatosis)
- sarcoidosis
- hilar lymphadenopathy
- pinna inflammation uncommon
- Behcet disease
- recurrent oral ulcers & genital ulcers[11]
Complications
- myelodysplastic syndrome has been reported in several patients with relapsing polychondritis
- ulceration & perforation of the cornea
- pericarditis & myocarditis
- 50% of deaths due to respiratory complications
Management
- prednisone
- 40-60 mg PO QD for active chondritis or vasculitis
- taper after disease is controlled
- in some patients prednisone may be stopped
- 10-15 mg PO QD may be required to maintain remission
- NSAIDs for chronic disease management
- immunosuppressive agents
- indicated for patients who fail prednisone therapy
- azathiaprine
- cyclophosphamide
- cyclosporine or dapsone may benefit some patients
- rituximab of little benefit
- intraocular steroids plus systemic glucocorticoids for significant ocular inflammation
More general terms
Additional terms
References
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1951-53
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 173, 789
- ↑ Jump up to: 3.0 3.1 3.2 3.3 3.4 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018, 2022.
Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025 - ↑ Leroux G et al Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients. Arthritis Rheum 2009 May 15; 61:577 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19405005
- ↑ Rafeq S, Trentham D, Ernst A. Pulmonary manifestations of relapsing polychondritis. Clin Chest Med. 2010 Sep;31(3):513-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20692543
- ↑ Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol. 2004 Jan;16(1):56-61. PMID: https://www.ncbi.nlm.nih.gov/pubmed/14673390
- ↑ Chopra R, Chaudhary N, Kay J. Relapsing polychondritis. Rheum Dis Clin North Am. 2013 May;39(2):263-76. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23597963
- ↑ McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976 May;55(3):193-215. PMID: https://www.ncbi.nlm.nih.gov/pubmed/775252
- ↑ Jump up to: 9.0 9.1 Haslag-Minoff J, Regunath H. Relapsing Polychondritis. Images in Clinical Medicine. N Engl J Med 2018; 378:1715. May 3, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29719184 https://www.nejm.org/doi/full/10.1056/NEJMicm1713302
- ↑ Vitale A, Sota J, Rigante D et al Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives. Curr Rheumatol Rep. 2016 Jan;18(1):3. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26711694
- ↑ Jump up to: 11.0 11.1 NEJM Knowledge+
Kingdon J, Roscamp J, Sangle S, D'Cruz D. Relapsing polychondritis: a clinical review for rheumatologists. Rheumatology (Oxford). 2018 Sep 1;57(9):1525-1532. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29126262 Review.
Longo L, Greco A, Rea A, Lo Vasco VR, De Virgilio A, De Vincentiis M. Relapsing polychondritis: A clinical update. Autoimmun Rev. 2016 Jun;15(6):539-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26876384 Review. - ↑ Mertz P, Costedoat-Chalumeau N, Ferrada MA, et al. Relapsing polychondritis: clinical updates and new differential diagnoses. Nat Rev Rheumatol. 2024;20:347-360. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38698240